Clinical trials: Patients With Tumor
Advanced Liver Cancer
OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients with Advanced Liver Cancer
An open-label dose-escalation phase I clinical study to evaluate the safety, tolerability and pharmacokinetics of OH2 injection via transcatheter Intraarterial infusion in patients with advanced hepatocellular carcinoma
- Trial name
- NCT05698459
- Testing
- OH2 injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Binhui Biopharmaceutical Co., Ltd.
Advanced Cancer, Cachexia
A Phase I Study on Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SXRN Plasmid DNA Technique in Patients With Advanced Solid Tumors
The purpose of this clinical trial is to evaluate the safety and tolerability of SXRN Plasmid DNA Technique in patients with advanced solid tumors.
- Trial name
- NCT06736275
- Testing
- SXRN
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Jiangsu Nutai Biologics Co., Ltd
Hematologic Malignancies
A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies
The purpose of this study is to determine the safety, maximum tolerated dose and pharmacokinetics of IPI-145 in patients with advanced hematologic malignancies.
- Trial name
- NCT01476657
- Testing
- IPI-145 (duvelisib)
- Where
- 4 sites in United States
- Volunteers
- 210 people
- Sponsor
- SecuraBio
Caregiver, Lobectomy Patient
Physical Activity Intervention Before and After Surgery in Older Adults With Lung Cancer and Their Family Caregivers
This trial studies whether a telephone-based physical activity intervention before and after lung cancer surgery can be provided to older patients and their caregivers.
- Conditions
- Caregiver, Lobectomy Patient, Lung Carcinoid Tumor, Lung Non-Small Cell Carcinoma
- Trial name
- NCT04085081
- Testing
- E-mail, Exercise Intervention, Quality-of-Life Assessment
- Volunteers
- healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Pain
A Safety and Efficacy Study of JNS024 Extended Release (ER) in Japanese and Korean Patients With Chronic Malignant Tumor-Related Cancer Pain
The purpose of this study is to evaluate the safety and efficacy of R331333 (referred to as JNS024 Extended-Release (ER) or CG5503) compared with an active comparator (oxycodone Controlled Release (CR)) in Japanese and Korean…
- Trial name
- NCT01165281
- Testing
- Oxycodone CR, R331333 (referred to as JNS024 ER or CG5503)
- Where
- 52 sites in Japan, South Korea
- Volunteers
- 343 people
- Sponsor
- Janssen Research & Development, LLC
Breast Cancer
Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel
The trial included screening period (4 weeks) and treatment period (4 treatment cycles, at least 12 weeks).
- Trial name
- NCT04514419
- Testing
- HS627, Pertuzumab
- Where
- China
- Volunteers
- 408 people
- Sponsor
- BioRay Pharmaceutical Co., Ltd.
Head and Neck Neoplasms, Carcinoma, Squamous Cell
A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck
This is a Phase 2, multi-center, open label study of ARQ 501 in patients with locally advanced, recurrent or metastatic squamous cell cancer of the head and neck (SCCHN).
- Trial name
- NCT00358930
- Testing
- ARQ 501
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Sarcoma
Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether ifosfamide alone is more effective than ifosfamide plus paclitaxel in treating…
- Trial name
- NCT00003128
- Testing
- filgrastim, ifosfamide, paclitaxel
- Where
- 17 sites in United States
- Volunteers
- 166 people
- Sponsor
- Gynecologic Oncology Group
Bladder Cancer, Breast Cancer
Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer
- Trial name
- NCT00004065
- Testing
- tanespimycin
- Where
- 2 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Solid Tumor, Non-Hodgkin's Lymphoma
First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas
The ATR (ataxia-telangiectasia and Rad3 related protein) inhibitor BAY1895344 is developed for the treatment of patients with advanced solid tumors and lymphomas.
- Conditions
- Advanced Solid Tumor, Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT03188965
- Testing
- Elimusertib (BAY1895344)
- Where
- 29 sites in United States, Canada and 5 more
- Volunteers
- 229 people
- Sponsor
- Bayer
Breast Cancer, Lung Cancer
Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
To characterize the safety and tolerability of NIS793 as single agent and in combination with PDR001 and to identify recommended doses for future studies.
- Conditions
- Breast Cancer, Lung Cancer, Hepatocellular Cancer, Colorectal Cancer
- Trial name
- NCT02947165
- Testing
- NIS793, PDR001
- Where
- 12 sites in United States, Austria and 7 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Non Small Cell Lung Cancer, Malignant Pleural Mesothelioma
Alvopem® (Pemetrexed) Safety Assessment
The present study was a phase IV, post-marketing, observational study for safety evaluation of Alvopem® use in Iranian patients with non-small cell lung cancer and malignant pleural mesothelioma.
- Trial name
- NCT04843007
- Testing
- Pemetrexed
- Volunteers
- 199 people
- Sponsor
- NanoAlvand
Bladder Cancer
Prognostic Biomarkers in Patients With Urothelial Carcinoma
Bladder cancer (BC) is a heterogeneous malignancy with dismal outcome.Despite treatment, the 5-year overall survival rates for MIBC are <50%, with many patients unresponsive or inapt, necessitating biomarkers to select those most…
- Trial name
- NCT04872036
- Volunteers
- 66 people
- Sponsor
- Hellenic Cooperative Oncology Group
Neoplasm Metastasis, Osteosarcoma
A Phase I Study of OncoLAR® (Registered Trademark) (NSC 685403) With/Without Tamoxifen in Patients With Osteosarcoma
The suppression of IGF-I and growth hormone may significantly alter the pathobiology of osteosarcoma. SMS 201-955 pa LAR is a long acting analog of Somatostatin which inhibits the pituitary release of growth hormone, reducing…
- Trial name
- NCT00001436
- Testing
- OncoLAR® (Registered Trademark), tamoxifen
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor, Adult, Advanced Solid Tumor
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with…
- Conditions
- Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer
- Trial name
- NCT05864144
- Testing
- SNS-101 (anti-VISTA), Cemiplimab
- Where
- 10 sites in United States
- Volunteers
- 98 people
- Sponsor
- Sensei Biotherapeutics, Inc.
Non-Small Cell Lung Cancer
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemotherapy administered prior to surgery compared with placebo and chemotherapy…
- Trial name
- AEGEAN (NCT03800134)
- Testing
- Durvalumab, Carboplatin, Cisplatin
- Where
- 231 sites in United States, Argentina and 26 more
- Volunteers
- 825 people
- Sponsor
- AstraZeneca
T-lymphoblastic Lymphoma, T-ALL
CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study
To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory T-LBL/ALL.
- Trial name
- NCT06136364
- Testing
- CAR-T
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Nasopharyngeal Neoplasms
Study Using Intensity-modulated Radiation Therapy in Patients With Nasopharynx Cancer to Permit Sparing of Contralateral Parotid Gland Function
One of the side effects of standard radiation therapy for cancer of the nasopharynx is a permanent lessening of normal mouth moisture (saliva).
- Trial name
- NCT00123864
- Testing
- Intensity-modulated radiation therapy
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- Alberta Health services
Cardiac Toxicity, Sarcoma
Combination Chemotherapy Before and After Surgery in Treating Patients With Osteosarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy before surgery may shrink the tumor so that it can be removed during surgery.
- Trial name
- NCT00019864
- Testing
- filgrastim, cisplatin, dexrazoxane hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- National Cancer Institute (NCI)
Reproductive Endocrinology, Polycystic Ovarian Syndrome
Metformin Improves Clinical Pregnancy Rate in Polycystic Ovarian Syndrome Patients
Polycystic ovary syndrome (PCOS) is the most common Female endocrine disorder , with a prevalence ranging between 6% to10% based on the National Institutes of Health (NIH) criteria and when the broader Rotterdam criteria are…
- Trial name
- NCT02562664
- Testing
- CC, Metformin
- Volunteers
- 66 people
- Sponsor
- Assiut University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.